{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:21:17Z","timestamp":1774081277941,"version":"3.50.1"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81770014"],"award-info":[{"award-number":["81770014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Clinical key specialist Construction Project (Tuberculosis)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Three months of weekly rifapentine plus isoniazid (3HP) is a short course regimen for latent tuberculosis infection treatment with satisfied safety and efficacy. However, research on its use in children is limited. In this study, we evaluated the completion rate and safety of the 3HP regimen among children in China. Participants aged 1\u201314 years receiving 3HP for TB prevention at Shanghai Public Health Clinical Center were followed from December 2019 to November 2020 to evaluate the safety and completion rate of the treatment. Thirty-one children were eligible for inclusion, but five were excluded from the analysis (three were treated with a lower than recommended dose, and two were lost to follow-up). Of the 26 children included in the analysis, the treatment completion rate was 100%. Adverse drug reactions (ADRs) were reported in 38.5% (10\/26) of the patients. The most common ADRs were gastrointestinal symptoms (19.2%,5\/26), and all ADRs were rated as Grade 1. The 3HP regimen has a high completion rate, and it seems well tolerated in our study population. However, further randomized controlled clinical trial with larger sample size are warranted.<\/jats:p>","DOI":"10.1371\/journal.pone.0253159","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T17:26:21Z","timestamp":1623432381000},"page":"e0253159","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection\u2014A single center study"],"prefix":"10.1371","volume":"16","author":[{"given":"Heng","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-dong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-ye","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-2907","authenticated-orcid":true,"given":"Shui-hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"pone.0253159.ref001","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"SL James","year":"2018","journal-title":"Lancet"},{"key":"pone.0253159.ref002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"GW Comstock","year":"1974","journal-title":"Am J Epidemiol"},{"key":"pone.0253159.ref003","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"MA Behr","year":"2018","journal-title":"BMJ"},{"key":"pone.0253159.ref004","first-page":"1799","article-title":"WHO\u2019s new end TB strategy","author":"M Uplekar","year":"2015","journal-title":"The Lancet. Lancet Publishing Group"},{"key":"pone.0253159.ref005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: A randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and Isoniazid","volume":"169","author":"ME Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"pone.0253159.ref006","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis","author":"GJ Njie","year":"2018","journal-title":"American Journal of Preventive Medicine. Elsevier Inc."},{"key":"pone.0253159.ref007","volume-title":"WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment","author":"World Health Organization","year":"2020"},{"key":"pone.0253159.ref008","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","article-title":"Exposure to latent tuberculosis treatment during pregnancy the PREVENT TB and the iadhere trials","author":"RN Moro","year":"2018","journal-title":"Annals of the American Thoracic Society. American Thoracic Society"},{"key":"pone.0253159.ref009","article-title":"Cost of delivering 12-dose isoniazid and rifapentine versus 6 months of isoniazid for tuberculosis infection in a high-burden setting","author":"CM Yuen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0253159.ref010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection","volume":"65","author":"AL Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0253159.ref011","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. U.S. Department of Health and Human Services, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"pone.0253159.ref012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"CA Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0253159.ref013","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018"},{"key":"pone.0253159.ref014","article-title":"Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial","author":"Q ling Ruan","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"pone.0253159.ref015","article-title":"Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: A randomised controlled study","volume":"52","author":"L Gao","year":"2018","journal-title":"Eur Respir J"},{"key":"pone.0253159.ref016","article-title":"Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection","author":"H-L Huang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0253159.ref017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and Other Systemic Drug Reactions among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study","volume":"61","author":"TR Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0253159.ref018","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection","volume":"365","author":"TR Sterling","year":"2011","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T17:26:40Z","timestamp":1623432400000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253159"}},"subtitle":[],"editor":[{"given":"Lei","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253159","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}